Editor's note
Neil Love, MD

FEATURING:

Gerald W Chodak, MD

Reserving lymph node dissection for patients at high risk
Early endocrine therapy in men with positive lymph nodes
Bicalutamide 150 mg versus castration in non-metastatic disease
Endocrine therapy in patients with PSA relapse
Treatment of patients at high risk for progression after local therapy
Informing patients about specific risks and benefits of treatments
Impact of earlier endocrine treatment on mortality
Selecting patients for maximum androgen blockade
Approaching decision-making with the prostate cancer patient
Importance of presenting patients with information

Select publications

Case 1: 52-year-old man with Gleason 8 prostate cancer and seminal vesicle invasion
Case 2: 60-year-old man with a T1c, Gleason 6 prostate cancer
Case 3: 64-year-old man with Gleason 7 prostate cancer, a positive margin and extracapsular penetration

Select publications

William Beaumont Hospital brachytherapy dose-escalation trial
ASTRO criteria for biochemical relapse after radiation therapy
Transient false-positive rises in PSA after radiation therapy ("PSA bounce")
Advantages of high-dose-rate brachytherapy
Quality control: Tracking prostate gland movement during radiation therapy
Surgical Prostatectomy versus Interstitial Radiation Intervention Trial (SPIRIT)

Select publications

Case 4: 69-year-old man with metastatic disease following initial primary
treatment with brachytherapy and external beam radiation therapy
Paclitaxel, estramustine and carboplatin for metastatic prostate cancer
Chemotherapy for palliation of advanced prostate cancer
A clinical trial randomizing to doxorubicin versus doxorubicin plus samarium

Select publications